ST. LOUIS, MO — November 11, 2025 — Leads & Copy — Stereotaxis (NYSE: STXS) reported its third-quarter financial results, which ended September 30, 2025. The company posted revenue of $7.5 million for the third quarter.
According to Chairman and CEO David Fischel, Stereotaxis is focused on commercial progress while advancing its technology portfolio through regulatory and development milestones.
Since the last quarterly call, two Genesis robotic systems have been ordered by European hospitals, establishing new robotic programs. Third-quarter recurring revenue reflects summer seasonality in procedure volumes, counteracted by momentum with Map-iT and launches of MAGiC and MAGiC Sweep.
MAGiC Sweep has garnered significant interest following recent FDA clearance, generating over $300,000 in revenue within the first two months of its launch. The company is focused on building a catheter portfolio with clinical and commercial impact.
The company announced U.S. FDA regulatory clearance for the GenesisX robotic system. They also announced European CE Mark receipt and FDA submission for their Synchrony digital cath lab technology. Multiple regulatory reviews are underway for new electrophysiology and vascular catheters, alongside a pipeline of catheter innovations. A collaboration with CardioFocus aims to advance the first robotically-navigated pulsed-field ablation electrophysiology catheter solution.
Key financial details include:
- Total revenue for the third quarter of 2025 reached $7.5 million.
- System revenue was $1.9 million, and recurring revenue was $5.6 million, compared to $4.4 million and $4.8 million, respectively, in the third quarter of the prior year.
- Gross margin for the third quarter was 55% of revenue; Recurring revenue gross margin reached 67%, and system gross margin was 19%.
- Operating loss and net loss were ($6.6) million and ($6.5) million, respectively, compared to ($6.3) million and ($6.2) million in the previous year.
- At September 30, 2025, Stereotaxis had cash and cash equivalents of $10.5 million and no debt.
Stereotaxis expects revenue in the fourth quarter of this year to exceed $9 million. This supports annual revenue growth for the current year of over 20%, in line with previous guidance of double-digit revenue growth for the full year 2025. Sustained growth of both system and recurring revenue is expected in 2026, with quarterly revenue surpassing an average of $10 million per quarter.
Kimberly R. Peery, Chief Financial Officer, 314-678-6100, Investors@Stereotaxis.com
Source: Stereotaxis
